Title:
Author: Joseph S. D'Arrigo*
Affiliation: Cavitation-Control Technology Inc., Farmington, CT 06032, USA.
*Corresponding author. E-mail: cavcon@netplex.net
Abstract:
Ultrasound-sensitive film-stabilized microbubbles (in a targeted nanoemulsion) are available. Versatile small-molecule drug(s) targeting
multiple pathways of Alzheimer's disease pathogenesis are known. Combined properly one is likely to obtain a multitasking combination therapeutic,
capable of readily targeting the multiple-cell-type network underlying Alzheimer's disease pathophysiology, for translational medicine. As one example,
Edaravone is a known promising drug candidate, to treat Alzheimer's disease, which is well-suited (based on low-molecular-weight and sufficient
lipophilicity) for incorporation into the LCM/ND lipid nanoemulsion proposed here to treat this disease. This recommendation is based in part on
knowledge of failed clinical trials indicating that a single target or pathway does not work on this complex disease, so recently investigators are
understandably encouraged by a drug like Edaravone which targets multiple pathways of Alzheimer's disease pathogenesis. By incorporating any such
drug candidates into the LCM/ND lipid nanoemulsion type, known to be a successful drug carrier, one is likely to obtain a multitasking combination
therapeutic for translational medicine. This therapeutic agent would target cell-surface SR-BI receptors making possible for various cell types, all
potentially implicated in Alzheimer's disease, to be simultaneously searched out and better reached for localized drug treatment. Lastly, a completely
separate and additional advantage of such LCM/ND lipid nanoemulsion(s), as a component of this multitasking combination therapeutic, stems from the
lipid-coated microbubble subpopulation existing in this nanoemulsion type. Specifically, such preformed (lipid-stabilized) microbubbles are well known
to substantially reduce the acoustic power levels needed for accomplishing noninvasive (transcranial) ultrasound treatment, or sonoporation, if
additionally desired for the Alzheimer's patient.
Introduction
The blood-brain barrier (BBB) is a tightly packed layer of cells that separates the bloodstream from brain tissue. While this circulatory anatomy
is highly effective at preventing contaminants in the blood from affecting the brain, the BBB creates some difficulties when trying to use medications
to target neurological disorders. Neuroscientists have been exploring the use of ultrasound and microbubbles to temporarily open the BBB, allowing
drugs or the immune system to target brain tumors or Alzheimer's brain plaque. It is believed ultrasound pulses make microbubbles expand and contract
against the BBB structure, thereby loosening the tight junctions of the cells forming the BBB (1,2). Recently, this research approach was employed by
G. Leinenga and J. Gotz, who utilized ultrasound coupled with intravenous injection of lipid-encased microbubbles. Their procedure design was
sufficient to both remove amyloid-B plaques in a mouse model of Alzheimer's disease, in which amyloid-B is deposited in the brain, and to restore
memory function in mice with Alzheimer's-like symptoms (1).
Transcranial Ultrasound
More specifically, these investigators report that repeated scanning ultrasound (SUS) treatments, of the mouse brain, activated the microglia (a type
of immune cell found in the brain) -- which in turn caused extensive internalization of amyloid-B plaques into the lysosomes of activated microglia
following the SUS treatments. Besides reducing plaque burden, the SUS-treated mice also displayed improved performance on three memory tasks (the
Y-maze, the novel object recognition test, and the active place avoidance task). Leinenga and Gotz conclude that their findings suggest that repeated
SUS is useful for removing amyloid-B plaques in the mouse brain without causing observable damage, and should be explored further as a noninvasive
method with potential as a therapeutic approach for Alzheimer's disease (1).
While noting that this concept of using ultrasound to clear out amyloid-B plaques is definitely intriguing, Prof. Terrence Town (of the University of Southern California) in a related news report (2) questions whether the above method can work in people without causing damage. He points out that Alzheimer's patients already have disrupted blood-brain barriers, so that any interaction of microbubbles (acoustically activated by ultrasound) with the BBB needs to be done very carefully so as not to make matters worse for the Alzheimer's patient (2). This expressed caution also has relevance to a recent review concerning therapies for Alzheimer's disease (3). The authors summarize the field by emphasizing that many of the therapeutic strategies tested (in animal models) have been successful, but none in humans. There is a striking deficit in translational research, i.e., to take a successful treatment in mice and translate it to the Alzheimer's patient. The authors assert that either the rodent models are not good, or we should extract only the most useful information from those animal models (3). In view of all the foregoing arguments, it appears likely that intravenous injection of film-stabilized microbubbles is quite useful since such preformed microbubbles are well known to substantially reduce the acoustic power levels needed for noninvasive (transcranial) ultrasound opening of the BBB (4-6), i.e., "sonoporation". This much lower ultrasound intensity (reduced acoustic forces) minimizes the chances of doing damage to healthy brain tissue in the Alzheimer's patient (as a result of over-permeation of the BBB, e.g., bleedings, inflammation and edema formation) (5).
Sonoporation
The structural mechanism for sonoporation by microbubbles/nanobubbles has very recently been studied (7) in more detail by performing molecular dynamics
computer simulations on systems that contained a model of the tight junctions from the BBB. When no bubble is present in the system, no damage to the
model tight junction is observed when the traveling shock (or sonic) wave propagates across it. However, in the presence of a nanobubble, even when
the impulse of the shock wave is relatively low, the implosion of the nanobubble causes significant structural change to their model tight junction
(7). These investigators further explain the structural mechanism of (lipid-bilayer) membrane poration, from shock wave (or sonic wave) induced
nanobubble collapse, through the use of (course-grain) molecular dynamics simulations. Specifically, in the absence of a nanobubble, shock pressure
is evenly distributed along the lateral area of the (modeled lipid-bilayer) membrane; whereas in the presence of a nanobubble an unequal distribution
of pressure on the membrane is created, leading to the membrane poration (8).
Receptor-Mediated Drug Delivery for Alzheimer's Disease
Moreover, by appropriate choice of film-stabilized microbubbles that can also carry a suitable drug across the BBB for localized delivery, it may be
possible for the ultrasound intensity (acoustic power level) to be lowered even further -- resulting in even smaller chances of doing any harm to
brain tissue in the patient. In actuality, various types of film-stabilized microbubble agent exist which can function as a drug carrier. However,
many of these preformed microbubble agents are incapable, after intravenous injection, of targeting any localized tissue sites or specific lesions.
While some of the remaining film-stabilized microbubble agents are capable of targeting, very few appear capable of searching out the appropriate
(cell-surface) receptors lining the vasculature of the human brain or within Alzheimer's disease sites in actual patients. Those Alzheimer's-disease-related
human receptors involve certain "lipoprotein receptors", including notably the (class B) scavenger receptor referred to as SR-BI (9) which has
been found to display significantly impaired function in Alzheimer's patients (10). In this study of humans (where, as in mice (11), SR-BI is well
established as a major high-density lipoprotein (HDL) receptor), HDL were isolated from 20 healthy subjects and from 39 Alzheimer's patients. The
anti-inflammatory activity of HDL was found to be significantly lower in Alzheimer's patients, which paralleled additional results revealing that
Alzheimer's disease had impaired the interaction of HDL with SR-BI receptors obtained from these patients. The authors conclude that their study,
using humans, provides evidence for the first time that the functionality of HDL is impaired in Alzheimer's disease, and that this alteration might
be caused by Alzheimer's-disease-associated oxidative stress and inflammation (10). More recently, Song et al. (12) have similarly showed that the
anti-inflammatory effects of HDL are dependent on SR-BI expression on macrophages also (another type of immune cell). These investigators point out
that besides HDL's role in regulating cholesterol metabolism, HDL has been shown to exhibit antioxidant and anti-inflammatory effects in the
vasculature (12). To now summarize the various cell types which all display cell-surface SR-BI and are potentially implicated in Alzheimer's disease,
the report by Thanopoulou et al. (11) should next be considered. These authors point out that SR-BI has been identified on astrocytes and vascular
smooth muscle cells in Alzheimer's disease brain, and has been demonstrated to mediate adhesion of microglia to fibrillar amyloid-B. As concerns
their own experiments, Thanopoulou et al. report that SR-BI mediates perivascular macrophage response, and regulates amyloid-B pathology and cerebral
amyloid angiopathy in an Alzheimer's mouse model (i.e., human-amyloid precursor protein transgenic mouse). The authors remark that these findings
designate SR-BI as a therapeutic target for treatment of Alzheimer's disease and cerebral amyloid angiopathy (8).
From all the foregoing findings in the preceding paragraph, it is evident that choosing an intravenous film-stabilized microbubble agent which targets cell-surface SR-BI could allow various above-described cell types, all potentially implicated in Alzheimer's disease, to be simultaneously searched out and likely reached for localized treatment (e.g., drug delivery). Due to the complexity of Alzheimer's disease, it is likely that therapeutics which target multiple cellular sites will result in a more efficient management of this disease, and might also be effective in various forms of Alzheimer's disease with different underlying pathophysiological mechanisms (13). As recently pointed out by Bredesen (14), there is not any single drug currently available for Alzheimer's disease that exerts anything beyond a marginal, unsustained symptomatic effect, with little or no effect on disease progression. Bredesen further states that, in the past decade alone, hundreds of clinical trials have been conducted for treating Alzheimer's disease, at an aggregate cost of literally billions of dollars, without success. However, for both Alzheimer's disease as well as its predecessors, mild cognitive impairment and subjective cognitive impairment, comprehensive combination therapies (targeting multiple cellular sites) have not been explored. It is also possible that targeting multiple cellular sites, within the multiple-cell-type network underlying Alzheimer's disease pathophysiology, may be successful even when each (SR-BI bearing) cell type targeted is affected in a relatively modest way; that is to say, the effects on the various cell types targeted may be additive, multiplicative, or otherwise synergistic (14).
Past Targeted Nanotherapy using Lipid Nanoemulsions
The above-stated desire for a multitasking combination therapeutic, capable of targeting (via SR-BI) the multiple-cell-type network underlying
Alzheimer's disease pathophysiology, would be further fulfilled if the chosen intravenous microbubble agent could readily and demonstrably carry (one
or more) useful small molecular drug(s). There is one multitasking therapeutic candidate, existing in the form of an intravenous film-stabilized
microbubble agent which targets cell-surface SR-BI, that is documented to be a successful carrier of selected small molecular compound(s).
Specifically, "lipid-coated microbubble (LCM) /nanoparticle-derived" lipid nanoemulsion, also known as LCM/ND lipid nanoemulsion type, is
well-documented (9) to be useful for highly selective delivery of (easily incorporated) lipophilic dyes, labels, or low-molecular-weight drugs to
various types of solid tumors and certain other (noncancerous) hyperproliferative-disease lesions/sites. All these lesions consistently display an
increased (cell-surface) expression and/or activity of lipoprotein receptors, including notably the (class B) scavenger receptor known as SR-BI (or
sometimes as CLA-1 [the human SR-BI ortholog] ). Such data on SR-BI expression and function are noteworthy; namely, SR-BI has emerged as the
lipoprotein receptor primarily involved in the enhanced endocytosis (i.e., enhanced intracellular uptake) of LCM/ND lipid nanoemulsions into
hyperproliferative-disease sites (9). First, as concerns tumors, an independent evaluation of this type of lipid nanoemulsion has appeared in a
review article by Constantinides et al. (15). At the same time, this particular study provides certain relevant data that is useful as a test of the
expectation that a significantly enhanced endocytosis of LCM/ND lipid nanoemulsion (likely mediated by SR-BI) ought to be readily detectable in Hep3B
human hepatoma cells. [This expectation arises from the fact that SR-BI expression, which is well described for HepG2 cells, has also been documented
in Hep3B cells. Furthermore, when studying the effect of chemical agents causing decreased SR-BI levels in Hep3B hepatoma cells, the same chemical
agents were observed to cause decreased uptake of HDL lipids into Hep3B cells (for a review see ref. 9).] In actuality, a noticeably enhanced uptake
of this (dye-carrying) LCM/ND lipid nanoemulsion type into varied tumor cells is reported by Constantinides et al. (15) and, as expected, the observed
enhanced uptake is particularly marked in Hep3B hepatoma cells (see Table 24.1 in ref. 9). The LCM/ND lipid nanoemulsion version employed by these
authors is called Emulsiphan. Most solid tumors displayed enhanced uptake of this Emulsiphan version of (dye-labeled) LCM/ND lipid nanoemulsion;
however, these tumors did not do so to the same degree. Nonetheless, it is noteworthy that all of the varied tumor cells listed in Table 24.1 (of
ref. 9) display a significantly increased uptake of this LCM/ND lipid nanoemulsion version (as compared to the undetectable level of Emulsiphan
nanoemulsion uptake in parenteral 3T3-L1 cells which are noncancerous cells). (For added discussion, see Sect. 24.3 in ref. 9.) Besides the above
dye-labeling experiments, both Constantinides et al. (15) and Ho et al. (16) have formulated LCM/ND lipid nanoemulsions with the anticancer drug,
paclitaxel, and documented the successful delivery of the carried drug (intracellularly) to various tumor cells (9).
As concerns the above-mentioned "certain other (noncancerous) hyperproliferative-disease lesions/sites", which overexpress scavenger receptors, one example is central nervous system (CNS) injury -- that is brain injury and/or spinal cord injury. Various published studies indicate increased scavenger receptor expression on "proliferating macrophages" and "activated astrocytes" arising after CNS injury. At the same time, this increased scavenger receptor expression, which probably mainly involves SR-BI (see Sect. 25.1.1 in ref. 9), provides a plausible avenue for targeted drug-delivery treatment of CNS-injury sites. Accordingly, Wakefield et al. (17) examined the use of LCM/ND lipid nanoemulsion to deliver 7B-hydroxycholesterol (7B-OHC) to a radiofrequency (thermal) lesion in the rat brain. [7B-OHC and other oxysterols have been reported, by other investigators, to inhibit astrogliosis both in vitro and in vivo (cf. 9).] Wakefield et al. observed that the number of activated astrocytes were reduced when treated with 7B-OHC delivered by the LCM/ND lipid nanoemulsion, while not affected by the same dose of intravenously injected 7B-OHC in saline. It appears that the mechanism of this enhanced delivery of 7B-OHC to the brain-injury site, by a LCM/ND lipid nanoemulsion type, shares common features with the above tumor work. (For added discussion, see Chap. 13 and Sect. 24.3 in ref. 9.) The above interpretation of the data receives additional indirect support from published findings, of other investigators, which document the expression of SR-BI on astrocytes and vascular smooth muscle cells in adult mouse and human brains -- as well as in Alzheimer's disease brain (9). Lastly, this documented ability of LCM/ND lipid nanoemulsion to function as a carrier of selected small molecular compounds would, of course, be potentially applicable to certain drug molecules already being used in research for treating Alzheimer's disease. Two such low-molecular-weight, and sufficiently lipophilic, candidates for incorporation into the LCM/ND lipid nanoemulsion are Edaravone (18) and caffeine (19-21).
Serum Amyloid A (SAA), SR-BI, and Alzheimer's Disease
The immune response after brain injury, and during neurodegenerative disorders, is highly complex -- involving both local and systemic events at the
cellular and molecular level (22). More specifically, inflammation of brain tissue in the absence of infection (sterile inflammation) contributes to
acute brain injury and chronic disease. Accordingly, Savage et al. have studied the inflammatory responses of glial cells in the presence of
a relevant endogenous priming stimulus; these authors report the acute-phase-protein serum amyloid A (SAA) [see below] acted as a sterile, endogenous,
priming stimulus on glial cells (23). Note that serum amyloid A (SAA) is a liver-derived "high-density lipoprotein (HDL)"-associated apolipoprotein,
whose level in the blood increases up to 1,000-fold in response to various injuries including trauma (e.g., CNS injury), inflammation (e.g., human
vascular plaques and Alzheimer's lesions), etc. Like other acute-phase reactants, the liver is the major site of SAA expression; however, SAA is
also expressed in cells at inflammation sites, e.g., macrophage cell lines and within human atherosclerotic lesions (e.g., 9). Baranova et al.
point out that the importance of SAA in various physiological and pathological processes has generated considerable interest in the identity of the
cell-surface receptor(s) that bind, internalize, and mediate SAA-induced proinflammatory effects. Furthermore, these authors assert that the results
of their study demonstrate that CLA-1 (the human SR-BI ortholog (25)) functions as an endocytic SAA receptor, and is involved in SAA-mediated
cell signaling events associated with the immune-related and inflammatory effects of SAA (24). In addition, CLA-1 and SR-BI are highly expressed
on monocytes/macrophages, cells known to be the primary sites of SAA uptake (24,26).
All the above observations, regarding SAA and inflammation, are noteworthy since inflammation is a known risk factor for Alzheimer's disease and the SAA concentration is much higher, in cerebrospinal fluid (CSF), in subjects with Alzheimer's disease than in controls (27). Miida et al. further found that SAA dissociated apolipoprotein E (apoE) from HDL, in the CSF, in a dose-dependent manner. Importantly, amyloid-B fragments [i.e., 1-42] were bound to large CSF-HDL, but not to apoE dissociated by SAA. These authors therefore postulate that inflammation in the CNS may impair amyloid-B clearance due to loss of apoE from CSF-HDL (27). Moreover, it has recently been independently reported that SAA itself can misfold and potentially lead to systemic amyloidoses (28).
Treating Brain Injury, Neuroinflammation, and Alzheimer's Disease via LCM/ND Nanoemulsions
The brief histological description of brain-injury sites, in the preceding three paragraphs, points to a larger pathophysiological overlap which
exists between brain injury and Alzheimer's disease brain. For example, Wang et al. (29) have pointed out that non-neuronal brain cells, especially
astrocytes (the predominant cell type in the human brain), may exert an active role in the pathogenesis of traumatic brain injury (TBI). Activated
astrocytes may contribute to increased oxidative stress and neuroinflammation following neurotrauma. Interestingly, the drug Edaravone (also
mentioned above [see 3 paragraphs back]) has been used successfully, in past research, for its neuroprotective and antioxidative effects on the brain
after TBI. Wang et al. (29) extended this research and found that, after intravenous administration (in rats), Edaravone treatment significantly
decreased hippocampal neuron loss, reduced oxidative stress, and decreased neuronal programmed cell death as compared to control treatment. The
protective effects of Edaravone treatment were also related to the pathology of TBI on non-neuronal cells, as Edaravone decreased both astrocyte and
microglia activation following TBI. These authors conclude that the likely mechanism of Edaravone's neuroprotective effect, in the rat model of TBI,
is via inhibiting oxidative stress leading to a decreased inflammatory response and decreased glial activation, and thereby reducing neuronal death
and improving neurological function (29). Similarly, Itoh et al. have reported that Edaravone administration intravenously (in rats), following TBI,
inhibited free radical-induced neuronal degeneration and apoptotic cell death around the damaged area. Hence, Edaravone treatment improved cerebral
dysfunction following TBI, suggesting its potential as an effective clinical therapy (30). In view of the above description of TBI, the effects of
the drug Edaravone, and the pathophysiological overlap of TBI with many characteristics of Alzheimer's disease brain (cf. above), it is logical and
consistent that Jiao et al. (18) have very recently reported that Edaravone can also ameliorate Alzheimer's disease-type pathologies and cognitive
deficits of a mouse model of Alzheimer's disease. Specifically, besides reducing amyloid-B deposition and tau hyperphosphorylation, Edaravone was
found to alleviate oxidative stress and, hence, attenuates the downstream pathologies including glial activation, neuroinflammation,
neuronal loss, synaptic dysfunction, and rescues the memory deficits of the mice (18). [Note that Edaravone is a small-molecule drug, which is known
to function as a free-radical scavenger; it currently is being used clinically in Japan to treat (acute ischemic) stroke patients (18,29).] Jiao et
al. further state that their above findings suggest that Edaravone is a promising drug candidate for Alzheimer's disease by targeting multiple key
pathways of the disease pathogenesis (18).
This recommendation by Jiao et al. of Edaravone (for treating Alzheimer's disease) fits well with the initial drug candidates suggested, based on low-molecular-weight and sufficient lipophilicity, for incorporation into the LCM/ND lipid nanoemulsion proposed here (cf. above) to treat Alzheimer's disease. Since their recommendation is based in part on knowledge of failed clinical trials indicating that a single target or pathway does not work on this complex disease (18), these investigators are understandably encouraged by a drug like Edaravone which targets multiple pathways of Alzheimer's disease pathogenesis.
Targeted Drug Delivery coordinated with Focused Sonoporation
More generally, this overall nanotherapeutic approach to treating Alzheimer's disease, via lipid(LCM/ND)-nanoemulsion particles, is in harmony with
the conclusions of a recent review on drug targeting to the brain (31). Of particular interest, Mahringer et al. point out that one non-invasive
approach to overcome the blood-brain barrier (BBB) has been to increase lipophilicity [even further] of CNS drugs by use of colloidal drug-delivery
carriers, e.g., surfactant/lipid-coated (polymeric) nanoparticles. These authors explain that, after intravenous injection, these surfactant-treated
nanoparticles apparently bind to apolipoproteins (e.g., apoA-I in blood plasma) and are subsequently recognized by the corresponding lipoprotein
receptors, e.g., SR-BI type scavenger receptors at the BBB (31; cf. Sect. 25.2 in ref. 9). In addition, Mahringer et al. further point out in their
review that focused-ultrasound/microbubble delivery of a model drug has been achieved with minimal histological damage, while demonstrating markedly
increased brain dosage (compared to background BBB "leak"), in transgenic Alzheimer's-disease mouse models (32). Moreover, in another related study,
the focused-ultrasound/microbubble strategy opened the BBB sufficiently to allow passage of compounds of at least 70 kDa (but not greater than 2,000
kDa) into the brain parenchyma. This non-invasive and localized BBB-opening (i.e., sonoporation) technique could, therefore, provide an applicable
mode to deliver nanoparticles of a range over several orders of magnitude of daltons (31,33).
Finally, (microbubble-assisted) sonoporation not only facilitates localized drug-delivery (cf. above) but also the removal of amyloid-B plaques from brain tissue in a mouse model (1). The mechanism of this plaque-burden reduction by sonoporation is believed to involve "loosening the tight junctions of the cells forming the BBB" (see Introduction); at the same time, it is worth noting that this same mechanism might also function to counteract characteristic decreased "brain clearance" of neurotoxic amyloid-B monomer which has been described (34) as a central event in the pathogenesis of Alzheimer's disease. Namely, the very recent biomolecular study by Keaney et al. reports that controlled modulation of tight junction components at the BBB can enhance the clearance (into the plasma) of soluble human amyloid-B monomers from the brain in a murine model of Alzheimer's disease (34).
Conclusions
By incorporating drug candidates (such as Edaravone) into the LCM/ND lipid nanoemulsion type, known to be a successful drug carrier (9), one is
likely to obtain a multitasking combination therapeutic for translational medicine. This therapeutic agent would target cell-surface SR-BI making
possible for various (above-described) cell types, all potentially implicated in Alzheimer's disease (cf. 35,36), to be simultaneously searched out
and better reached for localized drug treatment of brain tissue in vivo. Moreover, the effects of the various cell types targeted may be additive,
multiplicative, or otherwise synergistic. Hence the multitasking combination therapeutic may also display greater effectiveness at different stages
of Alzheimer's disease (cf. 35,36), resulting in a promising way to cure or prevent the disease in the future. Lastly, a completely separate and
additional advantage of such LCM/ND lipid nanoemulsion(s), as a component of this multitasking combination therapeutic, stems from the lipid-coated
microbubble subpopulation (9) existing in this nanoemulsion type. Specifically, such preformed (lipid-stabilized) microbubbles are well known to
substantially reduce the acoustic power levels needed for accomplishing noninvasive (transcranial) ultrasound treatment, or sonoporation (4-6,37,38),
if additionally desired for the Alzheimer's patient.
REFERENCES
1. G. Leinenga, J. Gotz, Scanning ultrasound removes amyloid-ß and restores memory in an Alzheimer's disease mouse model. Sci. Transl. Med. 7, 278ra33 (2015).
2. M. Torrice, Alzheimer's therapy goes acoustic. Chemical & Engineering News 93, (#11) 5 (2015).
3. R. Franco, A. Cedazo-Minguez, Successful therapies for Alzheimer's disease: Why so many in animal models and none in humans? Front. Pharmacol. 5, (June) 1-13 (2014).
4. C. Bing, M. Ladouceur-Wodzak, C. R. Wanner, J. M. Shelton, J. A. Richardson, R. Chopra, Trans-cranial opening of the blood-brain barrier in targeted regions using a stereotaxic brain axis and focused ultrasound energy. J. Ther. Ultrasound 2, (#13) 1-11 (2014).
5. T. Lammers, P. Koczera, S. Fokong, F. Gremse, J. Ehling, M. Vogt, A. Pich, G. Storm, M. van Zandvoort, F. Kiessling, Theranostic USPIO-loaded microbubbles for mediating and monitoring blood-brain barrier permeation. Adv. Funct. Mater. 25, 36-43 (2015).
6. F. Marquet, Y.S.Tung, T. Teichert, V.P. Ferrera, E.E. Konofagou, Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PloS ONE 6, e22598 (2011).
7. A. Goliaei, U. Adhikari, M.L. Berkowitz, Opening of the blood-brain barrier tight junction due to shock wave induced bubble collapse: a molecular dynamics simulation study. ACS Chem. Neurosci., doi:10.1021/acschemneuro.5b00116 (2015).
8. U.Adhikari, A. Goliaei, M.L. Berkowitz, Mechanism of membrane poration by shock wave induced nanobubble collapse: a molecular dynamics study. J. Phys. Chem. B 119, 6225-6234 (2015).
9. J. D'Arrigo, Stable Nanoemulsions: Self-Assembly in Nature and Nanomedicine, 415 pp. (Elsevier, Amsterdam, 2011).
10. A. Kahlil, H. Berrougui, G. Pawelec, T. Fulop, Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease. Mech. Ageing Dev. 133, 20-29 (2012).
11. K. Thanopoulou, A. Fragkouli, F. Stylianopoulou, S. Georgopoulos, Scavenger receptor class B typeI(SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc. Natl. Acad. Sci. U.S.A. 107, 20816-20821 (2010).
12. G. J. Song, S. M. Kim, K. H. Park, J. Kim, I. Choi, K. H. Cho, SR-BI mediates high density lipoprotein (HDL)-induced anti-inflammatory effect in macrophages. Biochem. Biophys. Res. Comm. 457, 112-118 (2015).
13. R. Donev, M. Kolev, B. Millet, J. Thome, Neuronal death in Alzheimer's disease and therapeutic opportunities. J. Cell. Mol. Med. 13, 4329-4348 (2009).
14. D. E. Bredesen, Reversal of cognitive decline: a novel therapeutic program. Aging (Albany, NY) 6, 707-717 (2014).
15. P. P. Constantinides, M. V. Chaubal, R. Shorr, Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60, 757-767 (2008).
16. S. Y. Ho, E. Barbarese, J. S. D'Arrigo, C. Smith, R. H. Simon, Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in tumor therapy. Neurosurgery 40, 1260-1268 (1997).
17. A. E. Wakefield, S. Y. Ho, X. G. Li, J. S. D'Arrigo, R. H. Simon, The use of lipid-coated microbubbles as a delivery agent for 7ß-hydroxycholesterol to a radiofrequency lesion in the rat brain. Neurosurgery 42, 592-598 (1998).
18. S. S. Jiao, X. Q. Yao, Y. H. Liu, Q. H. Wang, F. Zeng, J. J. Lu, J. Liu, C. Zhu, L. L. Shen, C. H. Liu, Y. R. Wang, G. H. Zeng, A. Parikh, J. Chen, C. R. Liang, Y. Xiang, X. L. Bu, J. Deng, J. Li, J. Xu, Y. Q. Zeng, X. Xu, H. W. Xu, J. H. Zhong, H. D. Zhou, X. F. Zhou, Y.J. Wang, Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. Proc. Natl. Acad. Sci. U.S.A. 112, 5225-5230 (2015).
19. S. Marques, V. L. Batalha, L. V. Lopez, T. F. Outeiro, Modulating Alzheimer's disease through caffeine: a putative link to epigenetics. J. Alzheimer's Dis. 24, 161-171 (2011).
20. S. Chieffi, M. La Marra, A. Viggiano, G. Messina, V. De Luca, M. Monda, Caffeine protection against ß-amyloid peptide toxicity in Alzheimer's disease. Current Topics in Peptide & Protein Res. 12, 71-75 (2011).
21. A. Mohan, A. J. Roberto, A. Mohan, L. Liogier-Weyback, R. Guha, N. Ravishankar, C. Rebello, A. Kumar, R. Mohan, Caffeine as treatment for Alzheimer's disease: a review. J. Caffeine Res., doi: 10.1089/jcr.2014.0027 (2015).
22. F. Orsini, D. De Blasio, R. Zangari, E. R. Zanier, M. G. De Simoni, Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front. Cell. Neurosci., doi: 10.3389/fncel.2014.00380 (2014).
23. C. D. Savage, G. Lopez-Castejon, A. Denes, D. Brough, NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front. Immunol., doi: 10.3389/fimmu.2012.00288 (2012).
24. I. N. Baranova, T. G. Vishnyakova, A. V. Bocharov, R. Kurlander, Z. Chen, M. L. Kimelman, A. T. Remaley, G. Csako, F. Thomas, T. L. Eggerman, A. P. Patterson, Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J. Biol. Chem. 280, 8031-8040 (2005).
25. T. G. Vishnyakova, A, V. Bocharov, I. N. Baranova, Z. Chen, A. T. Remaley, G. Csako, T. L. Eggerman, A. P. Patterson, Binding and internalization of lipopolysaccharide by CLA-1, a human orthologue of rodent scavenger receptor B1. J. Biol. Chem. 278, 22771-22780 (2003).
26. A. M. Pearson, Scavenger receptors in innate immunity. Curr. Opin. Immunol. 8, 20-28 (1996).
27. T. Miida, T. Yamada, U. Seino, M. Ito, Y. Fueki, A. Takahashi, K. Kosuge, S. Soda, O. Hanyu, K. Obayashi, O. Miyazaki, M. Okada, Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim. Biophys. Acta 1761, 424-433 (2006).
28. M. Das, O. Gursky, Amyloid-forming properties of human apolipoproteins: sequence analyses and structural insights. Adv. Exp. Med. Biol. 855, 175-211 (2015).
29. G. H. Wang, Z. L. Jiang, Y. C. Li, X. Li, H. Shi, Y.Q. Gao, P. S. Vosler, J. Chen, Free-radicle scavenger Edaravone treatment confers neuroprotection against traumatic brain injury in rats. J. Neurotrauma 28, 2123-2134 (2011).
30. T. Itoh, T. Satou, S. Nishida, M. Tsubaki, M. Imano, S. Hashimoto, H. Ito, Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats. Neurochem. Res. 35, 348-355 (2010).
31. A. Mahringer, V. Reichel, M. Ott, C. MacLean, I. Reimold, E. Hollnack-Pusch, G. Fricker, Overcoming the blood brain barrier: the challenge of brain drug targeting. J. Nanoneurosci. 2, 5-19 (2012).
32. S. B. Raymond, L. H. Treat, J. D. Dewey, N. J. McDannold, K. Hynynen, B. J. Bacskai, Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One 3, e2175 (2008).
33. J. J. Choi, S. Wang, Y. S. Tung, B. Morrison 3rd, E. E. Konofagou, Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med. Biol. 36, 58-67 (2010).
34. J. Keaney, D. M. Walsh, T. O'Malley, N. Hudson, D. E. Crosbie, T. Loftus, F. Sheehan, J. McDaid, M. M. Humphries, J. J. Callanan, F. M. Brett, M. A. Farrell, P. Humphries, M. Campbell, Autoregulated paracellular clearance of amyloid-B across the blood-brain barrier. Sci. Adv. 1, e1500472 (2015).
35. Y. J. Wang, Lessons from immunotherapy for Alzheimer's disease. Nat. Rev. Neurol. 10, 188-189 (2014).
36. D. Krstic, I. Knuesel, Deciphering the mechanism underlying late-onset Alzheimer's disease. Nat. Rev. Neurol. 9, 25-34 (2013).
37. A. Delalande, S. Kotopoulis, M. Postema, P. Midoux, C. Pichon, Sonoporation: mechanistic insights and ongoing challenges for gene transfer. Gene 525, 191-199 (2013).
38. V. Paefgen, D. Doleschel, F. Kiessling, Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery. Front. Pharm., doi: 10.3389/fphar.2015.00197 (2015).